Biologics Outsourcing Market
Biologics are the drugs generated from natural sources including human, animal, or microbial cells and consist of carbohydrates, proteins, or nucleic acids. Moreover, biologics include human cells and tissues, live attenuated microbes, allergenic extracts, cell and gene treatments. Biologics medicines are available for the treatment of disease such as chronic disease, cardiovascular disease, and so on.
Pharmaceutical companies had to outsource different stages of the biologic development and manufacturing process to highly effective service provider organizations due to the fast-paced nature of the biologic industry and the insufficient or absence of internal biologic development and manufacturing capabilities and capacities of biopharmaceutical companies. Major pharmaceutical corporations outsource the production of biologics to contract research organizations, contract manufacturing organizations, and others in order to concentrate on their core competencies while reducing operational costs.
Market Dynamics
Key market players are focused on inorganic strategies such as agreements to strengthen its product portfolio, is expected to drive the growth of global biologics outsourcing market over the forecast period. For instance, in November 2021, GenScript ProBio, a subsidiary of GenScript Biotech Corporation offering end-to-end CDMO services, announced that the company had entered into an agreement for cell line development, drug substance, and drug product manufacturing of therapeutic and diagnostic monoclonal antibodies (mAbs).
Key market players is focused on facility expansion to strengthen the company’s service and product portfolio, is expected to propel the growth of global biologics outsourcing market over the forecast period. For instance, in December 2022, Catalent, Inc. a pharmaceutical company, announced that it is establishing a new biologics analytical center of excellence in Durham, England, within North Carolina’s Research Triangle, to offer comprehensive standalone analytical development and testing for biologic drug modalities, including cell and gene therapies. The company planned to invest up to US$ 40 million to fit the 80,000 square-foot facility with equipment and instrumentation, including automation and digitization capabilities
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Detailed Segmentation:
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients